media – Page 19 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Planning a Share Swap to Absorb and Merge with Shanghai Raas

On December 22, Haier Biologics (688139) announced that the company is planning to absorb and merge with Shanghai Raas (002252) through a share swap, issuing A-shares to all shareholders of Shanghai Raas and raising matching funds through the issuance of A-shares. The company’s stock is set to be suspended from trading starting December 23 (Monday), with an expected suspension period not exceeding 10 trading days. Haier Biologics stated that during the suspension, the company will actively advance various tasks and, depending on the progress of the matter, will strictly comply with the relevant laws and regulations regarding information disclosure obligations. Once relevant matters are confirmed, the company will promptly release related announcements and apply for the resumption of trading of its stocks. Investors are encouraged to pay attention to subsequent announcements and be cautious about investment risks. On July 29, Shanghai Raas had previously announced a change in the company’s ...
- Source: drugdu
- 149
- December 26, 2024
BaiKe Biological’s Phase II Clinical Trial for Herpes Simplex Virus Type 2 mRNA Vaccine Approved

Shanghai Securities News reported on December 20 that BaiKe Biological announced in the evening that it recently received the “Clinical Trial Approval Notification” issued by the National Medical Products Administration, granting permission to conduct clinical trials for the prevention of genital herpes caused by Herpes Simplex Virus Type 2 (HSV-2) infection. The HSV-2 vaccine approved for clinical trials by the company was jointly submitted with Zhuhai Lifanda Biotechnology Co., Ltd. This vaccine is a multi-component vaccine capable of inducing both humoral immune responses and cellular immune responses, utilizing mRNA technology to further enhance the cellular immune response. Compared to traditional technology routes, it increases the likelihood of successful vaccine development. As of now, there are no related vaccine products successfully developed and marketed globally. BaiKe Biological stated that if this vaccine successfully completes its clinical trials and receives market approval, it will further enrich the company’s product pipeline, help optimize ...
- Source: drugdu
- 100
- December 26, 2024
CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine

CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine Finance China News, December 20 – CanSino (688185/06185) released a voluntary disclosure announcing the official launch of Phase II/III clinical trials for its adsorbed acellular DTaP (Diphtheria, Tetanus, and Pertussis) combined vaccine (for individuals aged 6 and older), having completed enrollment of the first subject in Phase II. This vaccine aims to provide booster immunization for adolescents and adults, filling a gap in the domestic market. Currently, the vaccine has completed Phase I clinical trials, with results indicating that its immunogenicity meets expectations and that it is safe. The ongoing Phase II/III clinical trials will further assess the vaccine’s immunogenicity and safety. The company will strictly advance the clinical trials in accordance with national drug registration regulations, despite the complexity and uncertainty inherent in the vaccine development process. In the first three quarters of 2024, CanSino achieved revenue ...
- Source: drugdu
- 72
- December 26, 2024
Medic West Africa

Organiser：Informa Markets Time：April 16 – 18, 2025 Address：10 Dr Nurudeen Olowopopo Way, Agidingbi, Ikeja Exhibition hall：Lagos International Conference and Exhibition Center Product range: Medical Devices: Blood pressure monitors, microscopes, audiometers, X-ray machines, CT scans, MRI machines, B-mode ultrasound scanners, biochemical analyzers, ECG machines, laser treatment machines, ventilators, blood bank equipment, medical video and photography equipment, aesthetic medical devices, orthopedic surgical equipment, etc. Medical Consumables: Operating room, emergency room, and consulting room instruments; surgical room clothing, shoes, and gloves; various medical surgical knives, clamps, scissors, disposable items, test tubes, adhesive bandages, masks, bandages, ear trumpets, tool kits, uniforms, syringes, etc. Rehabilitation Products: Orthopedic devices, walkers, massagers, health beds, medical beds, medical bathtubs, crutches, wheelchairs, health clothing, fitness equipment, etc. Healthcare Products: Household health and wellness products, small household diagnostic, monitoring, and treatment instruments; rehabilitation and physiotherapy instruments and supplies; oral and dental healthcare products and related items; health appliances, etc. ...
- Source: drugdu
- 181
- December 26, 2024
Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding

On December 23rd, Ikena Oncology and Inmage Biopharmaceuticals announced that they have signed a final merger agreement. The merged company will focus on developing IMG-007, a monoclonal antibody against OX40 for the treatment of atopic dermatitis. The merged company plans to operate under the name “ImageneBio” and trade on NASDAQ under the stock code “IMA”. This transaction is expected to generate approximately $175 million in funding to support the further development of IMG-007, including $75 million from oversubscribed private equity, which will be completed immediately after the merger This financing includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, as well as existing Ikena investors such as BVF Partners L.P., Blue Own Healthcare Opportunities, Omega Funds, and OrbiMed. Expected transaction to be completed by mid-2025 picture OX40 is a cost stimulating receptor that primarily exists on activated T cells. In placebo-controlled studies of atopic dermatitis, anti-OX40 mAb ...
- Source: drugdu
- 94
- December 25, 2024
Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved

NO.1 Two biosimilars of pertuzumab approved for market launch On December 23rd, the official website of the State Administration for Market Regulation showed that two types of pertuzumab injections were approved for market, one from Qilu Pharmaceutical and the other from Zhengda Tianqing. Patuximab was originally developed by Roche and was first approved for market by the FDA in 2012. It was first approved for market in China in 2018. Currently, multiple indications have been approved worldwide. Comment: Since its approval, the pertuzumab market has performed exceptionally well, with global sales of $4.2 billion in 2023. As a biosimilar drug, it is expected to occupy a certain market share in the original drug market. But currently, there are 7 domestic companies developing drugs similar to pertuzumab, and competition may intensify in the future. NO.2 Kangnuosipuqibai monoclonal antibody second indication approved On December 23rd, Konya announced that its independently developed ...
- Source: drugdu
- 95
- December 25, 2024
ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical

Hebei Jiheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Jiheng Pharmaceutical”) has signed a Motion OneCare worry free service agreement with ABB. Through ABB’s remote status monitoring and fault recovery services, the efficiency and quality of wastewater treatment have been improved, and the normal operation time of sewage pumps has been extended, thereby helping the entire pharmaceutical plant to operate smoothly at a larger capacity. Jiheng Pharmaceutical is located in Hengshui City, Hebei Province, about 250 kilometers south of Beijing, China. Its main products include painkillers, vitamin supplements, and pharmaceutical intermediates. Previously, Jiheng Pharmaceutical wanted to improve the reliability of mechanical vapor recompression (MVR) in the application of wastewater pumps driven by ten motors to enhance the stability of the production line. The MVR process can recover and reuse the energy lost during the evaporation process, thereby improving efficiency and saving energy. However, in recent years, unplanned shutdowns have occurred ...
- Source: drugdu
- 82
- December 25, 2024
CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed

01. CR Torch has officially become a subsidiary of Kunming Pharmaceutical Group On December 20-21, CR Sanjiu and Kunming Pharmaceutical Group successively announced the latest progress in the transfer of 51% equity of Kunming CR Torch. On December 20th, the relevant business registration procedures for the transfer of equity of CR Torch were completed. Kunming Pharmaceutical Group holds 51% of the equity of CR Torch, and CR Torch has become a subsidiary of Kunming Pharmaceutical Group and included in its consolidated financial statements. This also means that Kunyao Group, positioned as a leader in the silver hair health industry, has officially taken an important step towards strategic and professional integration of its Sanqi business. Next, Kunyao Group will continue to build itself into a benchmark enterprise in the Sanqi industry chain, further enhancing its market share in the field of cardiovascular and cerebrovascular products. The integration of two major pharmaceutical ...
- Source: drugdu
- 92
- December 25, 2024
CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine

Finance China News, December 20 – CanSino Biologics (688185/06185) released a voluntary disclosure announcing that its developed recombinant polio vaccine has initiated Phase I/II clinical trials in Indonesia, with the first subject enrolled in phase I. This vaccine utilizes virus-like particle technology, making it non-infectious, and is expected to perform well in terms of safety and immunogenicity. It is considered one of the preferred vaccines for the future eradication of polio, as recommended by the World Health Organization. This clinical trial will further assess the vaccination safety and immunogenicity of the vaccine in specific age groups of infants and young children. The announcement highlighted the complexity and uncertainty of vaccine development, stressing the unpredictability of the clinical trial process and results, advising investors to make cautious decisions. In the first three quarters of 2024, CanSino achieved revenue of 567 million yuan, with a net profit attributable to the parent company ...
- Source: drugdu
- 101
- December 25, 2024
Zhongshan Pharmaceutical’s “Class 1.1 Chinese Medicine for Gastric Diseases” has been approved for listing

Zhongshan Pharmaceutical’s application for listing of the new Chinese medicine 1.1 “Renshu Jianwei Granules” has been accepted. According to public information, the drug is intended to treat diseases such as atrophic gastritis and precancerous lesions of gastric mucosa. Atrophic gastritis is a disease in which the gastric pits become shallower due to the thinning of the gastric mucosa and the reduction or partial disappearance of intrinsic glands such as acid-secreting glands and mucous glands on the gastric mucosa. According to the degree of gland reduction, atrophic gastritis can be divided into mild, moderate and severe atrophy. Gastric mucosal carcinogenesis is a type of cancer caused by dysplasia of the gastric mucosa. Active treatment and intervention before dysplasia can prevent the occurrence of cancer. Among them, Chinese medicine, as an important category for the treatment of digestive tract and metabolic diseases, also plays a key role in various types of stomach ...
- Source: drugdu
- 117
- December 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.